<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718601</url>
  </required_header>
  <id_info>
    <org_study_id>GRN163L CP14A011</org_study_id>
    <nct_id>NCT00718601</nct_id>
  </id_info>
  <brief_title>Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma</brief_title>
  <official_title>A Phase I Study of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geron Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geron Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of
      GRN163L and Velcade with and without Decadron when administered to patients with refractory
      or relapsed multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety
      of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and
      is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in
      antineoplastic effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>First 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, PK and efficacy</measure>
    <time_frame>Baseline to 28 days after last dose of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 cohort dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imetelstat Sodium (GRN163L)</intervention_name>
    <description>25% dose escalation infused over 2 hours weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma (either secretory or nonsecretory disease)

          -  Relapsed or refractory disease

          -  ECOG performance status 0-2

          -  Adequate hepatic/renal function and platelet count

          -  If previously treated with an anthracycline, anthracenedione, or trastuzumab, must
             have left ventricular ejection fraction &gt; 50%

          -  Fully recovered from any previous cancer treatments and/or major surgery

        Exclusion Criteria:

          -  Prior allogeneic bone marrow transplant, including syngeneic transplant

          -  Bone marrow transplant within 12 weeks prior to study

          -  Known intracranial disease or epidural disease

          -  Inability to tolerate Velcade

          -  Inability to tolerate Decadron

          -  Prior malignancy (within the last 3 years)

          -  Clinically significant cardiovascular disease or condition

          -  Active or chronically recurrent bleeding (eg, active peptic ulcer disease

          -  Prolongation of PT or aPTT &gt; the ULN or fibrinogen &lt; the LLN

          -  Clinically relevant active infection

          -  Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or
             chronic restrictive pulmonary disease

          -  Any other cancer therapy within 4 weeks prior to study, with nitrosourea within 6
             weeks prior to study

          -  Investigational therapy within 4 weeks prior to study

          -  Anti-platelet therapy within 2 weeks prior to study, other than low dose aspirin
             prophylaxis therapy and low dose heparin administration for management of IV access
             devices

          -  Radiation therapy within 4 weeks prior to study

          -  Major surgery within 4 weeks prior to study

          -  Active autoimmune disease requiring immunosuppressive therapy

          -  Known positive serology for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Kelsey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Geron Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.geron.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <keyword>Relapsed or Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

